Zur Rose Group AG
- ISIN: CH0042615283
- Land: Schweiz
Nachricht vom 21.10.2020 | 06:50
Zur Rose Group accelerates growth in third quarter 2020
EQS Group-News: Zur Rose Group AG
/ Key word(s): Quarterly / Interim Statement
Zur Rose Group accelerates growth in third quarter 2020
- Revenue growth of 15.3 per cent in third quarter and considerable increase quarter-on-quarter
- Number of active customers across the Group rises to 9.8 million
- Share of the online pharmacy market in Germany rises to 43 per cent
- First shop-in-shop pharmacy opened in French-speaking Switzerland
- Implementation of the platform strategy moving ahead rapidly
- Market launch of full-service infrastructure for e-prescriptions in Germany
- Full year outlook confirmed
Considerable growth in all markets
Zur Rose and Medbase open the first shop-in-shop pharmacy in French-speaking Switzerland
Rapid implementation of the platform strategy in Germany and Switzerland
This is one more reason why the Zur Rose Group is continuing to drive forwards its digital ambitions. The launch of a first version of the DocMorris marketplace app is scheduled for the fourth quarter. The app eventually allows customers to choose whether to redeem their electronic prescriptions at a local pharmacy or online and enjoy further user-friendly applications ranging all the way to telemedical services as a major element of the healthcare platform. At the same time, pharmacy partners are able to offer their products and services, giving them easy, direct access to e-commerce. The intention is also to launch the marketplace model in Switzerland under the Zur Rose brand in 2021.
Again focusing on customer needs, in September 2020 Zur Rose launched the new digital medicines assistant Medi+ in Switzerland, jointly with health insurer KPT. Medi+ supports patients in taking and dealing with their medicines, helping to increase patient safety and avoid incorrect medication and the associated follow-up costs.
eHealth-Tec launches full-service infrastructure for electronic prescriptions
"By focusing on driving ahead the platform strategy with the eHealth-Tec e-prescription solution, which is being used by various healthcare players in model projects, and with almost 10 million active customers, we are well positioned as Europe's largest online pharmacy to successfully implement the long-term growth strategy", emphasises Walter Oberhänsli, CEO of the Zur Rose Group.
Investors and analyst contact
Zur Rose Group
The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,569 million (including medpex) and currently has around ten million active customers in core European markets.
With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.
The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com.
 As the separation of the mail-order business has not yet been completed, Medpex and Apotal had only a minor impact on the consolidated revenue of the Zur Rose Group.
|Company:||Zur Rose Group AG|
|Phone:||+41 52 724 08 14|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1142015|
|End of News||EQS Group News Service|
Event im Fokus
10. Juni 2021:Fachkonferenz Immobilien
14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure
13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie
10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix
„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“
Cryptology Asset Group PLC: 120 % Kurspotenzial
GBC Research hat mit der Coverage der Cryptology Asset Group PLC (ISIN: MT0001770107) begonnen. Die Bewertung der führenden europäischen Investmentgesellschaft für Krypto-Assets und Blockchain-Unternehmen erfolgte mittels der Berechnung des Net Asset Value (NAV). Unter Berücksichtigung aller Beteiligungen ergibt sich zum 05. Juli 2021 eine GBC-Fair-NAV-Bewertung in Höhe von 1,04 Mrd. EUR. Daraus ergibt sich ein NAV je Cryptology-Aktie von 358,43 EUR. Daher empfiehlt GBC Research die Cryptology-Aktie zum Kauf und sieht ein Kurspotenzial von über 120 %.
Der AKTIONÄR News
28. Juli 06:52 Volkswagen: Wichtige technische Marke!
News im Fokus
Delivery Hero startet globales Programm für nachhaltige Verpackungen zur Reduzierung von Plastikmüll
27. Juli 2021, 08:00
H1 2021 Analyst Call
04. August 2021
Original-Research: Vectron Systems AG (von GBC AG): Kaufen
28. Juli 2021